Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose...
-
HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
-
AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus monkeysPre-complexing...
-
For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle of treatment remains at 100% with a 38.5% complete response (CR) rate; one additional patient...
-
HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
-
100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cord...
-
HEIDELBERG, Germany, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
-
AFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022.AFM13 combination with NK cells: Updated data to be presented at company-sponsored event in...
-
HEIDELBERG, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
-
Patient recruitment is open for the first-in-human proof of concept trial of the combination of AFM24 and SNK01 NK cells in three advanced or metastatic EGFR-expressing cancers, namely non-small cell...